Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

(2021) Kristin B Highland et al.   Lancet Respiratory Medicine

Reduced humoral response to mRNA SARS‐CoV‐2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

(2021) Ayelet Grupper et al.   AMERICAN JOURNAL OF TRANSPLANTATION

BNT162b2 vaccination in heart transplant recipients: clinical experience and antibody response

(2021) Yael Peled et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

(2021) Liane Rabinowich et al.   JOURNAL OF HEPATOLOGY

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

(2021) Victoria Furer et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Dinesh Khanna et al.   Lancet Respiratory Medicine

Predictive Significance of Serum Interferon Inducible Protein Score for Response to Treatment in Systemic Sclerosis Related Interstitial Lung Disease

(2020) Shervin Assassi et al.   Arthritis & Rheumatology

Large‐Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis

(2020) Chiara Bellocchi et al.   Arthritis & Rheumatology

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

(2019) Oliver Distler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures

(2019) Shervin Assassi et al.   ANNALS OF THE RHEUMATIC DISEASES

Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II)

(2018) Suzanne Kafaja et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin

(2018) Monique Hinchcliff et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients

(2016) Romain Banchereau et al.   CELL

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

(2016) Donald P Tashkin et al.   Lancet Respiratory Medicine

Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus

(2015) Till Fassbinder et al.   ARTHRITIS RESEARCH & THERAPY

Quantitative set analysis for gene expression: a method to quantify gene set differential expression including gene-gene correlations

(2013) Gur Yaari et al.   NUCLEIC ACIDS RESEARCH

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

(2010) A. J. Tyndall et al.   ANNALS OF THE RHEUMATIC DISEASES

Systemic sclerosis and lupus: Points in an interferon-mediated continuum

(2010) Shervin Assassi et al.   ARTHRITIS AND RHEUMATISM

Robust Joint Modeling of Longitudinal Measurements and Competing Risks Failure Time Data

(2009) Ning Li et al.   BIOMETRICAL JOURNAL